[Efficacy and tolerability of highly crosslinked hyaluronic acid injections in the management of the enophthalmous orbit].
OBJECTIVE
Evaluation of the efficacy and tolerability of highly crosslinked hyaluronic acid injections in treating the enophthalmous orbit.


METHODS
Retrospective study of 11 enophthalmic patients who received an intraorbital injection of Juvederm(®) Voluma between June 2007 and October 2008. The mean follow-up was 19 months (range 12-25 months).


RESULTS
Twelve orbits of 11 patients were treated, including nine with post-enucleation socket syndrome (PESS). Volume loss was corrected in 66.67% of cases (eight orbits) with only one intraorbital injection. Two patients requested an additional injection, achieving a final success rate of 83.33%. A rate of 16.67% (two orbits) developed some bruising, mild swelling and hypersensivity at the injection site within 24 hours of administration of the filler, representing minor, temporary side-effects of which the patients had been forewarned. Persistent edema was noted in 16.67% of cases, likely due to an overcorrection of ptosis, and ptosis was exacerbated in 16.67% of cases (two orbits). One ptosis was corrected after several months, with no particular difficulties related to the hyaluronic acid. No additional complications were identified.


CONCLUSIONS
Juvederm(®) Voluma appears to be an effective filler for reduction of enophthalmos with a single intraorbital injection. In our experience, this product seems to have a longer duration of action than reported by the manufacturer and appears to perform like a semi-permanent or even permanent filler.
Service d'ophtalmologie, hôpital d'Instruction des Armées Percy, 101, avenue Henri-Barbusse, 92140 Clamart, France.
O
O
Crochelet
T
T
Maalouf
S
S
Duron
F
F
Froussart
J-C
JC
Rigal-Sastourné
J-L
JL
George
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D015331:Cohort Studies; D003432:Cross-Linking Reagents / Q000494:pharmacology; D015841:Enophthalmos / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000009:adverse effects* / Q000737:chemistry; D056965:Injections, Intraocular; D008297:Male; D008875:Middle Aged; D009916:Orbital Diseases / Q000188:drug therapy; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
D003432:Cross-Linking Reagents; D006820:Hyaluronic Acid